Effect of MD1003 in Spinal Progressive Multiple Sclerosis

Summary

The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment.

Timeline

Start

2013-10

Primary completion

2016-01

Completion

2018-01

Outcome

Met primary endpoint

release “today announces that the primary endpoint was met in its pivotal clinical trial MS-SPI.” medday-pharma.com ↗

release “the MS-SPI study’s primary endpoint was met” medday-pharma.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Biotin	Small molecule	100 mg	—

Indications